Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cephalothin is a first-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking. This leads to cell lysis and death, primarily in Gram-positive bacteria.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
FDA-approved: Treatment of respiratory tract infections, skin and soft tissue infections, bone and joint infections, septicemia, and urinary tract infections caused by susceptible organisms,Off-label: Prophylaxis in surgery, treatment of endocarditis
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
1-2 g IV every 4-6 hours; maximum 12 g/day.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
0.5-1 hour; prolonged in renal impairment (up to 8-12 hours in anuria)
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Cephalothin is metabolized in the liver by deacetylation to desacetylcephalothin, which has less antimicrobial activity. The enzyme responsible is not specifically identified but involves hepatic esterases.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Renal excretion (60-70% unchanged); biliary excretion (20-30%); fecal elimination (<1%)
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
65-80% bound to serum albumin
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
0.2-0.3 L/kg; primarily extracellular fluid
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
Intravenous: 100%; intramuscular: approximately 50-60%
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
Cr Cl 50-80 m L/min: no adjustment; Cr Cl 25-50 m L/min: 1-2 g every 6-8 hours; Cr Cl 10-25 m L/min: 1-2 g every 8-12 hours; Cr Cl <10 m L/min: 1-2 g every 12-24 hours.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
No specific dose adjustment recommended; use caution in severe hepatic impairment.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
100-150 mg/kg/day IV divided every 6 hours; maximum 12 g/day.
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
No specific adjustment; consider renal function and reduce dose if Cr Cl <50 m L/min.
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
None
None
Hypersensitivity reactions: Cross-allergenicity with other beta-lactams, including penicillins; anaphylaxis may occur,Pseudomembranous colitis: Clostridium difficile-associated diarrhea can develop,Renal impairment: Dosage adjustment required due to renal excretion; monitor renal function,Bleeding risk: May potentiate anticoagulants; monitor prothrombin time,False-positive urine glucose test: With Clinitest or Benedict's solution, but not with glucose oxidase methods
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Hypersensitivity to cephalothin, any cephalosporin, or other beta-lactam antibiotics,Absolute: Known anaphylactic reaction to penicillins due to cross-sensitivity
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
No significant food interactions. Absorption is not affected by food. Avoid alcohol during treatment and for 72 hours after completion to prevent disulfiram-like reaction (reported with some cephalosporins, though rare with cephalothin).
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
Cephalothin is a first-generation cephalosporin classified as FDA Pregnancy Category B. Animal reproduction studies have not demonstrated fetal risk, and there are no adequate and well-controlled studies in pregnant women. However, systemic absorption is expected to be low with intraperitoneal administration. First trimester: No evidence of teratogenicity, but data limited. Second/third trimesters: Generally considered safe; cross the placenta with therapeutic concentrations achieved in fetal serum and amniotic fluid. No known association with congenital malformations.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Cephalothin is excreted into human breast milk in low concentrations. The milk-to-plasma ratio is approximately 0.02–0.05. For a maternal dose of 1 g intravenously, the estimated infant dose is <1% of the therapeutic dose. Considered compatible with breastfeeding but monitor infant for potential gastrointestinal effects (e.g., diarrhea, candidiasis) or allergic reactions.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
Pregnancy-induced physiological changes (increased plasma volume, enhanced renal clearance) may reduce serum cephalothin concentrations. However, no formal dosing adjustments are recommended; standard adult dosing is used. For severe infections, monitor clinical response and consider higher doses if needed.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
Cephalothin is a first-generation cephalosporin with activity against gram-positive cocci (excluding MRSA and enterococci) and some gram-negative rods. It is often used perioperatively for surgical prophylaxis. Note that cephalothin is not active against Pseudomonas aeruginosa, Bacteroides fragilis, or Enterobacter species. Cross-allergenicity with penicillins occurs in approximately 5-10% of patients. Administer before meals if GI upset occurs. Monitor renal function in elderly or those with preexisting renal impairment, as cephalothin may accumulate and cause nephrotoxicity. Pain at injection site and phlebitis are common with IV administration.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
Take this medication exactly as prescribed, even if you feel well.,Complete the full course of therapy to prevent resistance.,Report any signs of allergic reaction such as rash, itching, swelling, or difficulty breathing immediately.,Inform your healthcare provider if you have a history of penicillin allergy.,If you experience severe diarrhea, especially with blood or mucus, contact your doctor (possible C. difficile colitis).,Use effective contraception during treatment, as cephalothin may reduce efficacy of oral contraceptives.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER is a Electrolyte that works by Cephalothin is a first-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking. This leads to cell lysis and death, primarily in Gram-positive bacteria.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER is: 1-2 g IV every 4-6 hours; maximum 12 g/day.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER is classified as Category A/B. Cephalothin is a first-generation cephalosporin classified as FDA Pregnancy Category B. Animal reproduction studies have not demonstrated fetal risk, and there are no adequate and . AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.